Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrevus in Relapsing Multiple Sclerosis
NCT04387734Phase 4Active, not recruiting
- Sponsor
- Georgia State University
- Start
- Feb 2021
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Georgia State University. Started Feb 2021; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04387734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387734.